ArticleScientific reports2025
LC/ESI-MS/MS phytochemical profiling and apoptotic effect of Haloxylon scoparium leaf extract on hepatocellular carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Natural Products in Cancer Prevention and Therapy: Current Challenges and Future Directions.MedComm · 2026Review
- Antitumor effect of alcohol extract ofFrontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Haloxylon scoparium, a plant native to Moroccan Sahara, was investigated for its potential anticancer activity against hepatocellular carcinoma (HCC). The study aimed to evaluate the effects of its methanolic extract on HCC and to conduct detailed chemical analysis using LC-ESI-MS/MS. In vitro cytotoxicity was assessed using HepG2 liver cancer cell line. In vivo experiments involved inducing HCC in mice with diethylnitrosamine (DEN). The study monitored inflammatory (TNF-α), apoptotic (BAX, Caspase-3, Caspase-8), and oncogenic markers (AFP, Bcl-2) through blood and liver tissue analysis. Liver histopathology was also performed to evaluate tissue-level changes. Mice survival rates were 83.33% in the DEN group and 91.67% in the DEN/H. scoparium group. Liver function markers (TBILR, ALP, AST) significantly decreased in the treatment group. TNF-α levels, elevated in DEN-only mice, were notably reduced after treatment. Oncogenic markers showed significant elevation in the DEN group but were decreased in the treatment group, whereas apoptotic markers were significantly elevated after treatment. Histopathology revealed more preserved liver architecture and scattered apoptotic foci in treated mice. Phytochemical profiling identified 27 compounds, including organic acids, phenolic acid derivatives, and flavonoids by LC/ESI-MS/MS. Molecular docking using AutoDock MGLTools 1.5.7 showed strong binding affinities of quercetin and isorhamnetin glycosides with cancer-related proteins (BCL-2, BAX, Caspases, AFP, TNF-α), supporting experimental results. 3D interaction models and box plots confirmed the stability and specificity of ligand-protein interactions. The study concludes that H. scoparium extract demonstrates promising multi-target anticancer potential and may serve as a valuable candidate for pharmaceutical development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.